StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)
StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research note issued to investors on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on ITCI. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to […]
StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research note issued to investors on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on ITCI. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to […]
